Receptors, Androgen

• 

  Subject Areas on Research

  • A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. 
  • A role for the androgen receptor in the treatment of male breast cancer. 
  • A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. 
  • Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. 
  • Actions of steroids in mitochondria. 
  • Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. 
  • Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. 
  • An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. 
  • Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. 
  • Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. 
  • Androgen and estrogen treatment, alone or in combination, differentially influences bone maturation and hypothalamic mechanisms that time puberty in the male rhesus monkey (Macaca mulatta). 
  • Androgen receptor activation by G(s) signaling in prostate cancer cells. 
  • Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. 
  • Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. 
  • Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. 
  • Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. 
  • Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. 
  • Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis. 
  • Androgen receptor-cofactor interactions as targets for new drug discovery. 
  • Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. 
  • Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. 
  • Bisphenol A affects androgen receptor function via multiple mechanisms. 
  • Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. 
  • CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. 
  • CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem. 
  • Cadmium-induced neoplastic transformation of human prostate epithelial cells. 
  • Characterization of androgen receptor in Sertoli cell-enriched testis. 
  • Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. 
  • Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. 
  • Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. 
  • Clinical results in cachexia therapeutics. 
  • Cloning of human androgen receptor complementary DNA and localization to the X chromosome. 
  • Combined effects of dietary phytoestrogen and synthetic endocrine-active compound on reproductive development in Sprague-Dawley rats: genistein and methoxychlor. 
  • Controversies in the treatment of prostate cancer with maximal androgen deprivation. 
  • Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. 
  • Copper signaling axis as a target for prostate cancer therapeutics. 
  • Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. 
  • DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations. 
  • Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors. 
  • Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate. 
  • Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. 
  • Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. 
  • Differences in steroid specificity for rat androgen binding protein and the cytoplasmic receptor. 
  • Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. 
  • Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. 
  • EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer. 
  • ELF3 is a repressor of androgen receptor action in prostate cancer cells. 
  • Enzalutamide in metastatic prostate cancer before chemotherapy. 
  • Evaluation and treatment of male and female pattern hair loss. 
  • Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. 
  • Evaluation of ligand-dependent changes in AR structure using peptide probes. 
  • Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. 
  • Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. 
  • Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients. 
  • Expression, purification and primary crystallographic study of human androgen receptor in complex with DNA and coactivator motifs. 
  • Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. 
  • Genetic alterations in prostate adenocarcinoma. 
  • Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 
  • Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis. 
  • Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. 
  • HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. 
  • Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. 
  • Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus. 
  • Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. 
  • Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. 
  • Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. 
  • Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. 
  • Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells. 
  • Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. 
  • Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. 
  • Interaction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies. 
  • International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. 
  • LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer. 
  • Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. 
  • Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46. 
  • Ligand-specific dynamics of the androgen receptor at its response element in living cells. 
  • Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. 
  • Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. 
  • Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. 
  • Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate. 
  • Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. 
  • MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. 
  • Molecular biology and function of the androgen receptor in genital development. 
  • Molecular determinants for enzalutamide-induced transcription in prostate cancer. 
  • Molecular implications of the antiandrogen withdrawal syndrome. 
  • Molecular mechanisms of development of the human fetal female reproductive tract. 
  • Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review. 
  • Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. 
  • Mutant and wild-type androgen receptors exhibit cross-talk on androgen-, glucocorticoid-, and progesterone-mediated transcription. 
  • Nemo-like kinase is a novel regulator of spinal and bulbar muscular atrophy. 
  • New treatment options in castration-resistant prostate cancer. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. 
  • Panel vs. single marker for discriminating desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma. 
  • Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. 
  • Pharmacological blockade of a β(2)AR-β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model. 
  • Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. 
  • Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. 
  • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. 
  • Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. 
  • Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. 
  • Precision Medicine Approaches When Prostate Cancer Akts Up. 
  • Preclinical and Coclinical Studies in Prostate Cancer. 
  • Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. 
  • Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. 
  • Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. 
  • Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. 
  • Prostate. III--A structural feature characteristic of the rat prostate 5 alpha-reductase active site. 
  • Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer. 
  • Proteome-wide muscle protein fractional synthesis rates predict muscle mass gain in response to a selective androgen receptor modulator in rats. 
  • Rare and low-frequency coding variants alter human adult height. 
  • Reduced prostate branching morphogenesis in stromal fibroblast, but not in epithelial, estrogen receptor α knockout mice. 
  • Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. 
  • Salivary testosterone and a trinucleotide (CAG) length polymorphism in the androgen receptor gene predict amygdala reactivity in men. 
  • Sexually dimorphic fin regeneration in zebrafish controlled by androgen/GSK3 signaling. 
  • Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors. 
  • Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. 
  • Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP). 
  • Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). 
  • TET2 binds the androgen receptor and loss is associated with prostate cancer. 
  • Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. 
  • Testosterone induction of song in photosensitive and photorefractory male sparrows. 
  • Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle. 
  • Testosterone supplementation upregulates androgen receptor expression and translational capacity during severe energy deficit. 
  • The Molecular Taxonomy of Primary Prostate Cancer. 
  • The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. 
  • The homeodomain protein HOXB13 regulates the cellular response to androgens. 
  • The production of androgen binding protein by Sertoli Cells. 
  • The role of testosterone in coordinating male life history strategies: The moderating effects of the androgen receptor CAG repeat polymorphism. 
  • The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer. 
  • Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. 
  • Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. 
  • Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. 
  • Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. 
  • Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide. 
  • Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. 
  • Use of phage display to identify novel mineralocorticoid receptor-interacting proteins. 
  • Using circulating tumor cells to inform on prostate cancer biology and clinical utility. 
  • Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. 
  • Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. 
  • X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Duke Innovation & Entrepreneurship
  • Moorman, Patricia Gripka, Professor in Family Medicine and Community Health, Duke Cancer Institute